Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Our ability to fund our projects enables us to execute and deliver on our mission.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
September 20, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 20, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City .
August 8, 2023
Conference call and webcast scheduled for Tuesday, August 8 , 4:30 p.m. Eastern Time . BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 8, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results.
August 1, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 1, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2023 financial results after the market closes on Tuesday, August 8, 2023 .
July 20, 2023
BRISBANE, Calif. & BOSTON --(BUSINESS WIRE)--Jul. 20, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered